In the labyrinthine landscape of the healthcare industry, where multiple players jostle for supremacy, few battles have been as intense and protracted as those between pharmaceutical companies and Pharmacy Benefit Managers (PBMs). This clash of titans isn’t merely a skirmish over market share or profit margins; it’s a struggle for control over the intricate web of drug pricing, distribution, and access. As the dust settles, it becomes increasingly evident that pharmaceutical CEOs are determined to rid themselves of PBMs, and here’s why.